Onconetix, Inc. ONCO
focused on the research, development, and commercialization of innovative solutions for men's health and oncology. Through our
acquisition of Proteomedix, which closed on December 15, 2023, we own Proclarix, an in vitro diagnostic test for prostate cancer originally
developed by Proteomedix and approved for sale in the European Union under the In Vitro Diagnostic Regulation ("IVDR"), which
we anticipate will be marketed in the U.S. as a lab developed test through our license agreement with LabCorp.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $815.4K | $2.5M | $58.5K | — | — | — |
| Cost of revenue | $182.5K | $1.5M | $1.2M | — | — | — |
| Gross profit | $632.9K | $1.1M | -$1.1M | — | — | — |
| R&D | — | $154.4K | $1.9M | $4.1M | $1.3M | — |
| SG&A | $7.0M | $11.2M | $14.8M | $9.4M | $2.1M | — |
| Total operating expenses | $18.5M | $57.5M | $34.9M | $13.5M | $3.4M | — |
| Operating income | -$17.9M | -$56.5M | -$36.0M | -$13.5M | -$3.4M | — |
| Interest expense | $751.0K | $873.4K | $671.6K | — | — | — |
| Pre-tax income | -$14.0M | -$59.7M | -$37.4M | -$13.4M | $675.73B | — |
| Income tax | $525 | $1.0M | $12.6K | $3.16T | $675.73B | — |
| Net income | -$14.0M | -$58.7M | -$37.4M | -$13.4M | -$3.4M | — |
| EPS, basic | -16.56 | -1,823.39 | -87.45 | -1.10 | -1.26 | — |
| EPS, diluted | -16.56 | -1,823.39 | -87.45 | -1.10 | -1.26 | — |
| Shares, diluted (wtd. avg.) | $937.7K | $32.3K | $427.8K | $12.3M | $3.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $5.2M | $646.5K | $4.6M | $25.8M | $1.9M | $4.3M |
| Receivables | $296.9K | $25.7K | $149.7K | — | — | — |
| Inventory | $150.0K | $64.1K | $364.1K | — | — | — |
| Total current assets | $6.1M | $950.3K | $5.8M | $26.3M | $3.1M | — |
| Property, plant and equipment | $37.1K | $62.9K | $60.7K | $14.1K | $11.5K | — |
| Goodwill | $18.5M | $27.0M | $55.7M | — | — | — |
| Other intangibles | — | — | $25.4M | — | — | — |
| Total assets | $24.9M | $28.2M | $87.5M | $26.3M | $3.1M | — |
| Accounts payable | $1.8M | $3.8M | $5.3M | $1.5M | $582.6K | — |
| Total current liabilities | $9.1M | $18.3M | $17.2M | $3.9M | $1.6M | — |
| Total liabilities | $9.2M | $18.6M | $21.9M | $3.9M | $1.6M | — |
| Retained earnings | -$131.2M | -$115.7M | -$56.8M | -$19.4M | -$6.0M | — |
| Total equity | $15.8M | $8.5M | $1.4M | $22.4M | $1.4M | $4.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$9.7M | -$10.5M | -$13.6M | -$8.7M | -$2.0M | — |
| Depreciation and amortisation | $15.0K | $22.0K | $7.0K | $6.8K | $4.9K | — |
| Stock-based compensation | $74.3K | $438.7K | $329.8K | $2.0M | $130.1K | — |
| Capital expenditure | — | $28.5K | $3.3K | $9.3K | $1.9K | — |
| Investing cash flow | — | -$28.5K | -$8.6M | -$32.7K | -$1.9K | — |
| Financing cash flow | $14.5M | $6.7M | $1.0M | $32.5M | -$334.2K | — |
| Buybacks | — | — | $59.0K | $566.8K | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-027725.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |